Alan Colowick
Director/Board Member bei ACELYRIN, INC.
Vermögen: 20 124 $ am 31.03.2024
Profil
Alan B.
Colowick is the founder of Inventages II.
He currently holds director positions at InCarda Therapeutics, Inc., Xylocor Therapeutics, Inc., ReCode Therapeutics, Inc., ACELYRIN, Inc., and Alumis, Inc. Previously, he served as the Chief Executive Officer of Gloucester Pharmaceuticals, Inc. from 2008 to 2010, Chairman of Principia Biopharma, Inc. from 2017 to 2020, Chairman of VelosBio, Inc. from 2018 to 2020, Independent Director of Achaogen, Inc. from 2015 to 2017, Independent Director of Personalis, Inc. from 2019 to 2023, Director of Dimension Therapeutics, Inc. from 2015 to 2017, Director of Human Longevity, Inc. from 2016 to 2019, Independent Director of Harpoon Therapeutics, Inc. from 2021 to 2023, Vice President-European Medical Affairs at Amgen, Inc. from 1999 to 2005, Executive Vice President at Celgene Corp.
from 2010 to 2017, President-Oncology Division at Geron Corp.
from 2006 to 2008, Chief Medical Officer at Threshold Pharmaceuticals, Inc. from 2005 to 2006, Executive Partner & Private Equity at Sofinnova Investments, Inc. from 2017 to 2021, and Principal at Harvard University in 1999.
He obtained his undergraduate degree from The University of Colorado, graduate degree from Harvard T.H.
Chan School of Public Health, and doctorate from Stanford University School of Medicine.
Bekannte Unternehmensbeteiligungen
Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
---|---|---|---|---|
PERSONALIS, INC.
0,03% | 17.05.2023 | 13 506 ( 0,03% ) | 20 124 $ | 31.03.2024 |
Aktive Positionen von Alan Colowick
Unternehmen | Position | Beginn |
---|---|---|
ACELYRIN, INC. | Director/Board Member | 01.11.2021 |
ReCode Therapeutics, Inc.
ReCode Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology ReCode Therapeutics, Inc. operates as a biopharmaceutical company. It develops precision medicines for pulmonary diseases. The company is headquartered in Irvin, TX. | Director/Board Member | 29.06.2022 |
Xylocor Therapeutics, Inc.
Xylocor Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Xylocor Therapeutics, Inc. engages in the biopharmaceutical company that develops gene therapy for people with advanced coronary artery disease. It focuses on developing product for patients with refractory angina with no treatment options and its secondary product for patients with cardiac tissue damage from heart attacks. The company was founded by Ronald Crystal and Todd Rosengart in 2013 and is headquartered in Malvern, PA. | Director/Board Member | 01.10.2018 |
InCarda Therapeutics, Inc.
InCarda Therapeutics, Inc. BiotechnologyHealth Technology InCarda Therapeutics, Inc. develops cardiovascular disease treatment through pulmonary delivery of established drugs. It also develops an inhaled therapy intended to treat paroxysmal atrial fibrillation. The company was founded by Narasimhan Rangachari, John S. Patton, Gregory M. Marcus and Carlos A. Schuler in 2009 and is headquartered in Newark, CA. | Director/Board Member | 01.10.2017 |
Alumis, Inc.
Alumis, Inc. Pharmaceuticals: MajorHealth Technology Alumis, Inc. is a precision medicines company called Esker that aims to provide personalized treatments for people with autoimmune diseases. The company is based in San Francisco, CA. Esker uses a precision analytics platform, powered by foresite labs, and a team of experts with deep experience in precision medicine drug discovery, development, and immunology to create medicines that change the lives of people with autoimmune disease. The company was founded by June H Lee. Martin Babler has been the CEO of the company since 2021. | Director/Board Member | 01.01.2022 |
Ehemalige bekannte Positionen von Alan Colowick
Unternehmen | Position | Ende |
---|---|---|
HARPOON THERAPEUTICS, INC. | Director/Board Member | 22.06.2023 |
PERSONALIS, INC. | Director/Board Member | 12.06.2023 |
Sofinnova Investments, Inc.
Sofinnova Investments, Inc. Investment ManagersFinance Sofinnova Investment Inc (Sofinnova Investment) is a venture capital firm founded in 1976 by Jacques F. vallle & Joel F. Martin. The firm is headquartered in Menlo Park, California. | Private Equity Investor | 01.01.2021 |
VelosBio, Inc.
VelosBio, Inc. Miscellaneous Commercial ServicesCommercial Services VelosBio, Inc. operates as an biopharmaceutical company. It developes antibody-drug conjugates to treat hematological cancers and solid tumors. The company was founded in 2017 and is headquartered in San Diego, CA. | Chairman | 31.12.2020 |
░░░░░░░░░ ░░░░░░░░░ ░░░░ | ░░░░░░░░ | ░░░░░░░░░░ |
Ausbildung von Alan Colowick
The University of Colorado | Undergraduate Degree |
Harvard T.H. Chan School of Public Health | Graduate Degree |
Stanford University School of Medicine | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 6 |
---|---|
AMGEN INC. | Health Technology |
GERON CORPORATION | Health Technology |
AC IMMUNE SA | Health Technology |
PERSONALIS, INC. | Health Services |
HARPOON THERAPEUTICS, INC. | Health Technology |
ACELYRIN, INC. | Health Technology |
Private Unternehmen | 17 |
---|---|
Celgene Corp.
Celgene Corp. BiotechnologyHealth Technology Celgene Corp. is an integrated global biopharmaceutical company, which engages in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases. Its primary commercial stage products include Revlimid, Pomalyst, Imnovid, Otezla, Abraxane, and Vidaza. The company was founded by David Stirling and Sol Barer in 1986 and is headquartered in Summit, NJ. | Health Technology |
Threshold Pharmaceuticals, Inc.
Threshold Pharmaceuticals, Inc. BiotechnologyHealth Technology Threshold Pharmaceuticals, Inc. engages in the development of therapeutics for treating tumors. It offers the Evofosfamide which designed as a prodrug that is activated under the extreme hypoxic conditions commonly found in tumors, but not typically in healthy tissues, and TH-3424 which is a small-molecule drug candidate for the treatment of liver, castrate resistant prostate cancer, T-cell acute lymphoblastic leukemias, and other cancers. The company was founded by Jeffrey W. Bird on October 17, 2001 and is headquartered in South San Francisco, CA | Health Technology |
Achaogen, Inc.
Achaogen, Inc. Pharmaceuticals: MajorHealth Technology Achaogen, Inc. engages in developing and commercializing innovative antibacterial agents for multi-drug resistant gram-negative infections. The firm is also involved in the development of C-Scape, an orally administered antibiotic to address a serious unmet need for an effective oral treatment for patients with complicated urinary tract infections, including pyelonephritis caused by extended spectrum beta-lactamases producing Enterobacteriaceae. The company was founded by Nathaniel Eames David, Floyd E. Romesberg, and Peter G. Schultz in June 2002 and is headquartered in South San Francisco, CA. | Health Technology |
Gloucester Pharmaceuticals, Inc.
Gloucester Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Gloucester Pharmaceuticals, Inc. develops products for the treatment of cancer patients. Its programs include cutaneous T-cell lymphoma (CTCL), peripheral T-cell lymphoma (PTCL), and multiple myeloma. The company was founded in May 2003 and is headquartered in Cambridge, MA | Health Technology |
Naryx Pharma, Inc.
Naryx Pharma, Inc. Pharmaceuticals: MajorHealth Technology Naryx Pharma, Inc. developd products for the treatment of chronic sinusitis. Its products were focused on inhaled, nebulizer, intranasal drug formulations. Its products include Sybryx, which is used for the treatment of chronic sinusitis. The company focused on development of inhaled, nebulized, and intranasal drug formulations. The company was founded in 1999 and was headquartered in Carpinteria, CA. | Health Technology |
Celgene International SARL
Celgene International SARL Pharmaceuticals: MajorHealth Technology Founded in 2010, Celgene International SARL is a Swiss bio-pharmaceutical company that operates to discover, develop, and commercialize therapies for unmet medical needs in cancer. Part of Bristol Myers Squibb Co., the private company is based in Boudry, Switzerland. | Health Technology |
Principia Biopharma, Inc.
Principia Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Principia Biopharma, Inc. is a biopharmaceutical company, which engages in designing and developing oral therapies to patients with significant unmet medical needs in immunology and oncology. It operates through Tailored Covalency platform, which enables to develop small molecule inhibitors of enzymes and receptor ligands with potencies and selectivities that rival those of injectable biologics, yet maintain the convenience of a pill. Its product pipeline includes PRN1008, PRN2246, PRN1371, and immunoproteasome inhibitor. The company was founded by Jack Taunton and Richard A. Miller on October 6, 2008 and is headquartered in South San Francisco, CA. | Health Technology |
Sofinnova Investments, Inc.
Sofinnova Investments, Inc. Investment ManagersFinance Sofinnova Investment Inc (Sofinnova Investment) is a venture capital firm founded in 1976 by Jacques F. vallle & Joel F. Martin. The firm is headquartered in Menlo Park, California. | Finance |
Nora Therapeutics, Inc.
Nora Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Nora Therapeutics, Inc. develops therapeutics to address clinical unmet needs in reproductive medicine. Its's lead product NT100, seeks to improve pregnancy outcomes in women undergoing in vitro fertilization or who have suffered recurrent spontaneous miscarriages. The company was founded by Darryl L. Carter and Chris B. McClain in 2007 and is headquartered in Palo Alto, CA. | Health Technology |
Inventages II
Inventages II Investment ManagersFinance Inventages II invests in companies located in Bahamas. The fund focus on companies such as life science and consumer applications. It provides financing for seed, early and buyout capital requirements. | Finance |
InCarda Therapeutics, Inc.
InCarda Therapeutics, Inc. BiotechnologyHealth Technology InCarda Therapeutics, Inc. develops cardiovascular disease treatment through pulmonary delivery of established drugs. It also develops an inhaled therapy intended to treat paroxysmal atrial fibrillation. The company was founded by Narasimhan Rangachari, John S. Patton, Gregory M. Marcus and Carlos A. Schuler in 2009 and is headquartered in Newark, CA. | Health Technology |
Dimension Therapeutics, Inc.
Dimension Therapeutics, Inc. BiotechnologyHealth Technology Dimension Therapeutics, Inc. engages in the development of novel treatments for rare diseases. Its activities include discoveries and development of therapeutic products for people living with rare diseases associated wit the liver and caused by genetic mutations. The company was founded by Ben Auspitz in June 20, 2013 and is headquartered in Cambridge, MA. | Health Technology |
Human Longevity, Inc.
Human Longevity, Inc. BiotechnologyHealth Technology Human Longevity, Inc. provides precision health analytics to individuals through the Health Nucleus. The Health Nucleus is an assessment of current and future risk for cardiac, oncologic, metabolic and cognitive diseases and conditions. The firm offers database of sequenced genomes and phenotypic data. The company was founded by J. Craig Venter, Robert Joseph Hariri Gordon, and Peter H. Diamandis in 2013 and is headquartered in San Diego, CA. | Health Technology |
Xylocor Therapeutics, Inc.
Xylocor Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Xylocor Therapeutics, Inc. engages in the biopharmaceutical company that develops gene therapy for people with advanced coronary artery disease. It focuses on developing product for patients with refractory angina with no treatment options and its secondary product for patients with cardiac tissue damage from heart attacks. The company was founded by Ronald Crystal and Todd Rosengart in 2013 and is headquartered in Malvern, PA. | Health Technology |
ReCode Therapeutics, Inc.
ReCode Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology ReCode Therapeutics, Inc. operates as a biopharmaceutical company. It develops precision medicines for pulmonary diseases. The company is headquartered in Irvin, TX. | Health Technology |
VelosBio, Inc.
VelosBio, Inc. Miscellaneous Commercial ServicesCommercial Services VelosBio, Inc. operates as an biopharmaceutical company. It developes antibody-drug conjugates to treat hematological cancers and solid tumors. The company was founded in 2017 and is headquartered in San Diego, CA. | Commercial Services |
Alumis, Inc.
Alumis, Inc. Pharmaceuticals: MajorHealth Technology Alumis, Inc. is a precision medicines company called Esker that aims to provide personalized treatments for people with autoimmune diseases. The company is based in San Francisco, CA. Esker uses a precision analytics platform, powered by foresite labs, and a team of experts with deep experience in precision medicine drug discovery, development, and immunology to create medicines that change the lives of people with autoimmune disease. The company was founded by June H Lee. Martin Babler has been the CEO of the company since 2021. | Health Technology |